Site icon pharmaceutical daily

China’s Butylphthalide Market Report 2021-2025 and the Impact of COVID-19 on the Chinese Butylphthalide Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Butylphthalide Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Butylphthalide, developed by CSPC Enbipu Pharmaceutical Co. Ltd is used to treat mild to moderate acute ischemic stroke. Its soft capsule was approved in China in 2005, and its injection was approved in China in 2010. In 2009, Butylphthalide soft capsules were included in the Medicines List for National Basic Medical Insurance in China. In 2017, Butylphthalide injection was included in the Medicines List for National Basic Medical Insurance in China. By 2020, the only manufacturers are CSPC Enbipu Pharmaceutical Co. Ltd. in the Chinese Butylphthalide market.

According to this analysis report, the sales of Butylphthalide have grown from 2016 to 2020. Especially, the annual growth rate is more than 30%, after the price cut through negotiations in 2019. Its sales have increased the most obviously, from CNY1.22 billion in 2018 to CNY 1.59 billion in 2019. The CAGR of the sales of Butylphthalide in the Chinese market from 2016 to 2020 is 14.7%.

The analyst predicts that as the price of Butylphthalide will decrease, the sales volume of Butylphthalide will keep a rising trend from 2021 to 2025. Butylphthalide was once again listed as a drug for medical insurance price negotiations in 2020. It can be expected that the price will drop by about 50% after the negotiation is successful, which will lead to an increase in sales as the price drops. Moreover, Butylphthalide injections and patented capsules will expire in 2022 and 2023 respectively. After the patent expires, many companies will participate in the market competition. The price will drop with the addition of new manufacturers. The sales volume and sales will grow accordingly.

Furthermore, with the increase of population aging, the incidence of some diseases continues to rise, prompting the demand for Butylphthalide in the Chinese market.

Topics Covered:

Key Topics Covered:

1 Relevant Concepts of Butylphthalide

1.1 Indications for Butylphthalide

1.2 Development of Butylphthalide in China

1.3 Governmental Approval of Butylphthalide in China

1.4 The Impact of COVID-19 on Butylphthalide sales in China

2 Sales of Butylphthalide in China, 2016-2020

2.1 Sales Value of Butylphthalide

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Butylphthalide

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Butylphthalide by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Soft Capsules

3 Analysis of Major Butylphthalide Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Butylphthalide Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 CSPC Enbipu Pharmaceutical Co. Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of NBP (CSPC Enbipu Pharmaceutical Co. Ltd.’s Butylphthalide) in China

3.3 Analysis of Other companies

4 Prices of Butylphthalide for Different Manufacturers in China, 2020-2021

4.1 CSPC Enbipu Pharmaceutical Co. Ltd. (NBP)

4.2 Analysis of Other companies

5 Prospect of Chinese Butylphthalide Market, 2021-2025

5.1 Influential Factors of Chinese Butylphthalide Market Development

5.1.1 The Impact of COVID-19 on Chinese Butylphthalide Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/u15ku1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version